Phocaeicola Vulgatus Test

Phocaeicola vulgatus (P. vulgatus) is one of the most abundant bacteria in the human gut. It belongs to the Bacteroidetes phylum, a group of organisms central to carbohydrate breakdown and immune regulation in the colon. Despite being a normal resident of the gut, P. vulgatus has a dual personality: it can promote health in some situations and contribute to disease in others, depending on the balance of the microbial ecosystem and the host’s immune state.

Metabolic and Cardiovascular Roles

Under healthy conditions, P. vulgatus helps break down complex carbohydrates and produce beneficial metabolites, such as short-chain fatty acids (SCFAs). Experimental research shows that it can improve lipid metabolism and reduce liver fat accumulation by producing 3-hydroxyphenylacetic acid (3-HPAA), a compound that regulates fat synthesis and inflammation. In mouse models, supplementation with P. vulgatus also reduced atherosclerosis (plaque buildup in arteries) by lowering gut-derived lipopolysaccharide (LPS), a bacterial molecule that can trigger systemic inflammation when it leaks into the bloodstream.

Immune and Inflammatory Effects

While P. vulgatus can protect against infections such as Vibrio cholerae, its abundance is also associated with inflammatory bowel diseases (IBD) like ulcerative colitis. Excess P. vulgatus or strains with high protease activity can damage the intestinal barrier, leading to inflammation and worsening disease severity. This demonstrates how the same microbe that supports gut health in balance can become harmful when it dominates.

Systemic Health Connections

Beyond the gut, P. vulgatus has been linked to several systemic effects. High levels have been associated with lower bone density, possibly due to inflammatory signaling and reduced valeric acid, a short-chain fatty acid with bone-protective effects. In liver cirrhosis patients, increased P. vulgatus abundance after transjugular intrahepatic portosystemic shunt (TIPS) surgery correlated with higher ammonia levels and a greater risk of hepatic encephalopathy, a brain complication of liver failure.

Emerging cancer research also implicates P. vulgatus in resistance to anti-PD-1 immunotherapy for liver cancer, possibly through decreased production of indoleacetic acid, a microbial metabolite that supports immune T cell activity.

Microbial Ecology and Therapeutic Potential

P. vulgatus is not just a passive resident; it shapes its microbial neighborhood. It produces antibacterial toxins that selectively inhibit related gut species, potentially influencing the balance between beneficial and harmful microbes, including pathogens like Clostridioides difficile. It is also known to host crAssphage, one of the most common bacteriophages (viruses that infect bacteria) in the human gut, which may regulate its population and behavior.